Fri Oct 04 04:44:04 UTC 2024: ## ABL Bio and MSD Partner to Evaluate Bispecific Antibody ABL103 in Combination with KEYTRUDA for Solid Tumors

**SEONGNAM, South Korea – October 4, 2024** – ABL Bio, a South Korean biotechnology company specializing in bispecific antibodies, announced today a clinical trial collaboration and supply agreement with MSD (a subsidiary of Merck & Co., Inc.). The partnership will evaluate the safety and efficacy of ABL Bio’s ABL103 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA®, in patients with advanced or metastatic solid tumors.

ABL103 is a bispecific antibody targeting both B7-H4 and 4-1BB, designed to selectively activate T cells within the tumor microenvironment while minimizing liver toxicity. The drug utilizes ABL Bio’s proprietary ‘Grabody-T’ platform, which enhances antitumor activity and allows for targeted tumor cell destruction.

The phase 1b/2 clinical trial will be conducted by ABL Bio, with MSD supplying KEYTRUDA. MSD’s anti-PD-1 therapy works by boosting the immune system’s ability to fight cancer cells.

“We are excited to collaborate with MSD to evaluate the potential of ABL103 in combination with KEYTRUDA for patients with advanced or metastatic solid tumors,” said Sang Hoon Lee, CEO of ABL Bio. “This collaboration will allow us to move forward with the next stage of ABL103 clinical development and potentially improve the lives of patients with this challenging disease.”

This collaboration signifies ABL Bio’s commitment to developing innovative therapies for various cancers. The company currently has over 15 clinical projects underway for different assets, including ABL001, which recently received Fast Track designation from the FDA for its potential in treating certain cancers.

This news highlights the growing field of immunotherapy and bispecific antibody research. The combined power of ABL103 and KEYTRUDA could potentially offer a significant advancement in the treatment of advanced or metastatic solid tumors.

Read More